Effectiveness of an oral cholera vaccine in Zanzibar: Findings from a mass vaccination campaign and observational cohort study
MetadataShow full item record
Background: Zanzibar, in east Africa, has been severely and repeatedly affected by cholera since 1978. We assessed the effectiveness of oral cholera vaccination in high-risk populations in the archipelago to estimate the indirect (herd) protection conferred by the vaccine and direct vaccine effectiveness. Methods: We offered two doses of a killed whole-cell B-subunit cholera vaccine to individuals aged 2 years and older in six rural and urban sites. To estimate vaccine direct protection, we compared the incidence of cholera between recipients and non-recipients using generalised estimating equations with the log link function while controlling for potential confounding variables. To estimate indirect effects, we used a geographic information systems approach and assessed the association between neighbourhood-level vaccine coverage and the risk for cholera in the non-vaccinated residents of that neighbourhood, after controlling for potential confounding variables. This study is registered with . ClinicalTrials.gov, number . NCT00709410. Findings: Of 48 178 individuals eligible to receive the vaccine, 23 921 (50%) received two doses. Between February, 2009, and May, 2010, there was an outbreak of cholera, enabling us to assess vaccine effectiveness. The vaccine conferred 79% (95% CI 47-92) direct protection against cholera in participants who received two doses. Indirect (herd) protection was shown by a decrease in the risk for cholera of non-vaccinated residents within a household's neighbourhood as the vaccine coverage in that neighbourhood increased. Interpretation: Our findings suggest that the oral cholera vaccine offers both direct and indirect (herd) protection in a sub-Saharan African setting. Mass oral cholera immunisation campaigns have the potential to provide not only protection for vaccinated individuals but also for the unvaccinated members of the community and should be strongly considered for wider use. Because this is an internationally-licensed vaccine, we could not undertake a randomised placebo-controlled trial, but the absence of vaccine effectiveness against non-cholera diarrhoea indicates that the noted protection against cholera could not be explained by bias. Funding: Bill & Melinda Gates Foundation, Swedish International Development Cooperation Agency, and the South Korean Government. © 2012 Elsevier Ltd.
Showing items related by title, author, creator and subject.
Safety of a killed oral cholera vaccine (Shanchol) in pregnant women in Malawi: an observational cohort studyAli, Mohammed; Nelson, A.; Luquero, F.; Azman, A.; Debes, A.; M'bang'ombe, M.; Seyama, L.; Kachale, E.; Zuze, K.; Malichi, D.; Zulu, F.; Msyamboza, K.; Kabuluzi, S.; Sack, D. (2017)© 2017 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY license Background Pregnancy increases the risk of harmful effects from cholera for both mothers and their fetuses. A killed ...
Deen, J.; Ali, Mohammed; Sack, D. (2014)There is increasing interest to use oral cholera vaccination as an additional strategy to water and sanitation interventions against endemic and epidemic cholera. There are two internationally-available and WHO-prequalified ...
Potential for Controlling Cholera Using a Ring Vaccination Strategy: Re-analysis of Data from a Cluster-Randomized Clinical TrialAli, Mohammed; Debes, A.; Luquero, F.; Kim, D.; Park, J.; Digilio, L.; Manna, B.; Kanungo, S.; Dutta, S.; Sur, D.; Bhattacharya, S.; Sack, D. (2016)© 2016 Ali et al. Introduction: Vaccinating a buffer of individuals around a case (ring vaccination) has the potential to target those who are at highest risk of infection, reducing the number of doses needed to control ...